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Abstract
Agonist binding to K2-adrenoceptors is modulated by a number of factors such as Mg2 and Na ions and by experimental
manipulations which interfere with receptor^G-protein-coupling such as pertussis toxin pre-treatment or the presence of
guanine nucleotides. Agonist binding assays may therefore offer an opportunity to make inferences, albeit indirect, about
receptor states or conformations and about the molecular nature of the processes involved in receptor activation. We have
investigated possible differences in the effects of Na ions on the binding of agonists to the three human K2-adrenoceptor
subtypes, K2A, K2B and K2C, recombinantly expressed in S115 mouse mammary tumour cells. NaCl (40 mM) influenced the
apparent affinity of a panel of K2-adrenoceptor ligands in a complex compound- and subtype-dependent manner. Sodium
ions affected both high- and low-affinity conformations of the receptors, as defined by co-incubation with 10 WM
5P-guanylylimidodiphosphate (Gpp(NH)p). The effects of NaCl and Gpp(NH)p on agonist binding were additive indicating
different modes of action for the two allosteric modulators. Thus, quite marked differences between closely related receptor
subtypes were noted in the molecular details of agonist^receptor interactions and in the integration of allosteric modulation
by Na ions. Possible explanations for the experimental findings are discussed within the theoretical framework of multi-
state models, and a proposal is presented for a potential physiological role of the modulatory effect of Na ions, where
intracellular Na concentrations would direct the activating influence of receptors to different G-proteins. ß 1998 Elsevier
Science B.V. All rights reserved.
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1. Introduction
K2-Adrenoceptors belong to the family of G-pro-
tein-coupled receptors (GPCR). Three human
K2-adrenoceptor subtype genes, K2-C10, K2-C4 and
K2-C2, have been cloned [1^3] and assigned to the
pharmacologically de¢ned receptor subtypes K2A,
K2C and K2B [4]. The coupling of receptors to guanine
nucleotide regulatory proteins (G-proteins) has been
investigated intensively due to its pivotal role in sig-
nal transduction.
The conceptualisation of GPCR function at the
molecular level has seen signi¢cant changes in recent
years. Classically, receptors were viewed as essen-
tially static entities which underwent conformational
changes from inactive (or resting) to activated states
only after being triggered by an agonist. However,
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this notion of receptors as agonist-activated switches
is di⁄cult to reconcile with experimental observa-
tions indicating receptor activity in the absence of
agonists.
A more recent concept regards GPCR as dynamic
entities, in which binding interactions between
closely situated amino acid residues and peptide do-
mains are constantly formed or broken and which
therefore constantly undergo spontaneous conforma-
tional changes. This enables the receptor protein to
occasionally access activated conformations even in
the absence of agonists. The role of ligands in this
concept is viewed more as one of stabilising receptor
conformations rather than triggering their formation.
A number of multi-state models with varying de-
grees of sophistication have been presented in the
literature (for a summary see Kenakin [5]). The sim-
plest of them, the so-called two-state model, requires
only three parameters to describe a receptor system:
the a⁄nities of a ligand for the activated and resting
state, respectively, and an equilibrium constant cor-
responding to the ratio of receptors in the resting
state over those in the activated state in the absence
of any ligand [6]. Proposals for multiple state recep-
tor models have often been motivated by attempts to
account for shallow or even heterogeneous agonist
competition binding curves. However, as has been
pointed out by Lee et al. [7] in a theoretical analysis
of the ternary complex model, such derivations from
Langmuirian adsorption isotherms can not be ex-
plained by multi-state models as long as complete
interconversion between states is assumed. An essen-
tially identical conclusion has been drawn by Neubig
et al. [8] based on experimental data for the K2-adre-
noceptor in human platelets. The latter authors also
demonstrated that the heterogeneous binding proper-
ties of platelet K2-adrenoceptors were best modelled
by dividing the receptor population into a couplable
and a noncouplable subset.
Agonist binding to K2-adrenoceptors has been
shown to be a¡ected by a number of factors such
as Mg2 and Na ions and by experimental manip-
ulations which interfere with receptor^G-protein-
coupling such as pertussis toxin pre-treatment or
the presence of guanine nucleotides. Agonist binding
assays may therefore allow indirect inferences to be
made about receptor states and conformational
changes.
Sodium ions modulate agonist binding to a num-
ber of GPCR. In the case of the porcine K2A-adre-
noceptor the allosteric e¡ect of Na has been as-
cribed to interactions with a speci¢c residue (Asp
79) located on the cytoplasmic face of the second
transmembrane domain [9]. This aspartate is con-
served in all three human K2-adrenoceptor subtypes,
as well as in most other GPCR [10^12], and modu-
lation by Na ions has been shown for a number of
K2-adrenoceptor preparations [12^20]. The existence
of a highly conserved aspartate residue in many
GPCRs together with the widespread occurrence
of allosteric modulation by Na ions can be taken
as an indication for a physiological role of this phe-
nomenon. In this regard it is relevant to mention
that manipulation of the intracellular Na concen-
tration has been shown to modulate agonist a⁄nity
of K2-adrenoceptors present on intact human plate-
lets [14].
The current study utilised recombinant human
K2-adrenoceptor subtypes (K2A, K2B, K2C) expressed
in S115 mouse mammary tumour cells. One purpose
of the study was to investigate possible di¡erences in
the e¡ects of Na ions on the binding of agonists to
the three human K2-adrenoceptor subtypes. Such dif-
ferences between closely related receptor subtypes
may shed light on the molecular details of agonist^
receptor interactions and the integration of allosteric
modulation by Na ions in that process. A second
goal was to try to gain insight into the mode of
action of allosteric modulation by Na ions by view-
ing the phenomenon from the perspective of the dy-
namic receptor concept.
2. Materials and methods
2.1. Cell culture and preparation of cell homogenates
Recombinant lines of Shionogi 115 (S115) mouse
mammary tumour cells stably expressing the human
K2-adrenoceptor subtypes K2A, K2B and K2C (K2-C10,
K2-C2 and K2-C4) [21,22] were cultured in roller
bottles (1400 cm2, Nunclon) in DMEM (Dulbecco’s
modi¢ed Eagle’s medium) supplemented with 20 mM
Hepes, 20 mM NaHCO3, 5% heat-inactivated foetal
calf serum, 100 U/ml penicillin, 50 Wg/ml streptomy-
cin, 1 mM sodium pyruvate and 10 nM testosterone.
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The cells were grown in 5% CO2 at 37‡C. Cells were
harvested into chilled phosphate-bu¡ered saline, pel-
leted and stored frozen at 370‡C; the stability of the
receptors has been previously demonstrated [22]. Cell
pellets were washed twice before experiments with
incubation bu¡er (NMDG: 25 mM glycylglycine;
40 mM Hepes; 5 mM EGTA; 10 mM MgCl2 ;
75 mM N-methyl-D-glucamine (NMDG); pH 7.4,
or NMDG+NaCl: 25 mM glycylglycine; 40 mM
Hepes; 5 mM EGTA; 10 mM MgCl2 ; 35 mM
NMDG; 40 mM NaCl; pH 7.4). Cells were pelleted
by centrifugation (42 000Ug, 15 min) at 4‡C and
then homogenised with an Ultra-Turrax homogeniser
(15 s) in ice-cold incubation bu¡er, and pelleted
again by centrifugation (42 000Ug, 15 min) at 4‡C.
The pellet was resuspended in ice-cold incubation
bu¡er just before use and rehomogenised. The osmo-
lality of the binding medium was thus held constant
in the presence and absence of 40 mM NaCl with
35 or 75 mM NMDGCl3 bu¡er. In some experi-
ments, 40 mM LiCl or KCl were used instead of
40 mM NaCl. Protein concentrations were deter-
mined with the method of Bradford [23] with bovine
serum albumin as the reference standard.
2.2. Binding assays
All incubations were performed in triplicate in a
25‡C water bath with shaking. Receptor binding was
measured by incubating 100 Wl of cell homogenate
(30^90 Wg of protein) with the radioligand
[3H]RX821002 in a total volume of 250 Wl in the
absence (75 mM NMDG) or presence of 40 mM
NaCl (35 mM NMDG). After 30 min, the incuba-
tions were terminated by dilution with 2 ml of ice-
cold bu¡er and rapid ¢ltration through glass ¢bre
¢lters (Whatman GF/B) using a Brandel M-48R
(Gaithersburg, MD, USA) cell harvester in a cold
room (6‡C). The ¢lters were washed twice with 5 ml
of ice-cold bu¡er and placed into scintillation vials
with OptiPhase ‘HiSafe’ III (Wallac, Turku, Finland)
for counting at 45% e⁄ciency (Wallac 1410, Wallac).
Speci¢c binding was de¢ned as the di¡erence be-
tween total and non-speci¢c binding determined in
parallel sets of tubes but in the presence of an excess
of (3)-adrenaline (100 WM).
For kinetic studies of the association reaction, cell
homogenates were incubated with [3H]RX821002 at
25‡C for periods of time ranging from 1 to 60 min.
The reaction was terminated by ¢ltration. Reversibil-
ity of [3H]RX821002 binding was assessed by ¢rst
incubating the samples to steady state and then add-
ing an excess of competing drug (100 WM (3)-adren-
aline) to prevent the re-association of dissociated
[3H]RX821002. Speci¢c binding was determined at
time points between 1 and 60 min. The association
kinetics of (3)-noradrenaline was studied using re-
versibility of [3H]RX821002 binding as indicator,
with (3)-noradrenaline concentrations close to its
Ki-value at each receptor subtype (determined in
the presence of 40 mM NaCl). In saturation binding
experiments, the ¢nal concentrations of radioligand
ranged from 0.06 to 20 nM [24].
Competition studies were performed using
[3H]RX821002 concentrations close to its equilibrium
dissociation constant (Kd) at each receptor subtype
and 13^15 concentrations of the competitors, in the
presence and absence of the GTP-analogue,
Gpp(NH)p (10 WM), which eliminates high-a⁄nity
binding of agonists to K2-adrenoceptors [21,24,25].
2.3. Calculations
Equilibrium dissociation constants (Kd) and recep-
tor densities (Bmax) were calculated from the results
of saturation experiments using computer-assisted
data analysis with the EBDA-LIGAND package
(Elsevier Biosoft, Cambridge, UK), a non-linear least
squares computer program (McPherson, 1985). Asso-
ciation and dissociation data were analysed with the
KINETIC module of the LIGAND program pack-
age. Inhibition constants (Ki) for competing drugs
were calculated with GraphPAD programs (Graph-
PAD Software and PRISM, San Diego, CA, USA)
applying the Cheng^Pruso¡ equation [26]. Agonist
competition curves in the absence of Gpp(NH)p
were analysed assuming a two-site binding model,
although the ¢t was not always statistically signi¢-
cantly better to this model than to a one-site model.
One-site models were used for results obtained in the
presence of Gpp(NH)p, as two-site analysis did not
provide statistically signi¢cantly better ¢ts than one-
site models (F-test).
The Kd- and Ki-values are presented as geometric
means þ S.E. and the other results as arithmetic
means þ S.E. Student’s t-test with two-tailed proba-
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bilities, or one-way analysis of variance (ANOVA)
together with the Student^Newman^Keuls-test were
used to test the statistical signi¢cance of the observed
di¡erences between group means.
2.4. Drugs and chemicals
[3H]RX821002 (speci¢c activity 48 Ci/mmol) was
from Amersham (Buckinghamshire, UK). Dexmede-
tomidine and L-medetomidine were gifts from Orion-
Farmos (Turku, Finland). Rauwolscine was from
Carl Roth (Karlsruhe, Germany), and RX821002
(2-[2-(2-methoxy-1,4-benzodioxanyl)]imidazoline hy-
drochloride), UK 14,304 (5-bromo-N-(4,5-dihydro-
1H-imidazol-2-yl)-6-quinoxalinamine) and K-methyl-
noradrenaline were from Research Biochemicals
(Natick, MA, USA). The following compounds
were obtained from Sigma (St. Louis, MO, USA):
(3)-adrenaline, (3)-noradrenaline, clonidine,
NMDG and 5P-guanylylimidodiphosphate (Gpp-
(NH)p). NaCl was from Merck (Darmstadt, Ger-
many). Cell culture reagents were supplied by Gibco
(Gaithersburg, MD, USA). Other chemicals were of
analytical or reagent grade, and were purchased from
commercial suppliers.
3. Results
3.1. Saturation binding
Equilibrium dissociation constants (Kd) and esti-
mates of receptor density (Bmax) were determined
with [3H]RX821002 in NMDG bu¡er in the absence
and presence of NaCl (40 mM) and Gpp(NH)p
(10 WM). The a⁄nities of all three human K2-adre-
noceptor subtypes for the antagonist radioligand
[3H]RX821002 were increased in the presence of
40 mM NaCl. The increase in a⁄nity was 1.5-fold
for K2A (P = 0.13), 3.5-fold for K2B (P6 0.01) and
3-fold for K2C (P6 0.01). Gpp(NH)p tended to in-
crease the a⁄nity of K2A for [3H]RX821002 in the
presence of NaCl (P6 0.01) and reduced the a⁄nity
of K2B for the radioligand (P6 0.01 in the presence
of NaCl but not statistically signi¢cant in the ab-
sence of NaCl) (Table 1). The Na-induced increase
in the a⁄nity of K2C for the radioligand was similar
in the absence and presence of Gpp(NH)p (P6 0.01).
Statistically signi¢cant changes were not noted in the
Bmax values. Other monovalent cations (Li, K)
had no e¡ects on the a⁄nity (Kd) of the K2A-subtype
for [3H]RX821002 (data not shown).
Table 1
Saturation binding of [3H]RX821002 to homogenates of S115 cells expressing recombinant human K2-adrenoceptors
Bu¡er Kd (nM) Bmax (fmol mg31) nH
K2A (clone S115-C10) (n = 3^8)
NMDG 1.86 þ 0.16 342 þ 69 0.98 þ 0.01
NMDG+Gpp(NH)p 1.97 þ 0.37n:s: 223 þ 78 1.00 þ 0.01
NMDG+NaCl 1.25 þ 0.36n:s: 401 þ 58 0.94 þ 0.02
NMDG+NaCl+Gpp(NH)p 0.68 þ 0.16** 349 þ 27 0.95 þ 0.02
K2B (clone S115-C2) (n = 3^6)
NMDG 15.5 þ 3.1 2688 þ 459 1.00 þ 0.01
NMDG+Gpp(NH)p 21.8 þ 1.1n:s: 2845 þ 16 0.99 þ 0.01
NMDG+NaCl 4.42 þ 0.40** 2664 þ 170 1.00 þ 0.01
NMDG+NaCl+Gpp(NH)p 9.08 þ 0.29** 2253 þ 450 0.95 þ 0.02
K2C (clone S115-C4) (n = 3^4)
NMDG 5.70 þ 0.14 1223 þ 315 1.00 þ 0.01
NMDG+Gpp(NH)p 5.59 þ 0.31n:s: 1139 þ 262 0.99 þ 0.01
NMDG+NaCl 1.95 þ 0.32** 866 þ 115 0.99 þ 0.01
NMDG+NaCl+Gpp(NH)p 1.86 þ 0.54** 1339 þ 22 0.97 þ 0.01
Experiments were performed in the absence and presence of 40 mM NaCl and 10 WM Gpp(NH)p added either alone or in combina-
tion. Speci¢city of binding was determined with 100 WM (3)-adrenaline. Values are means þ S.E. from 3^8 separate experiments per-
formed in triplicate. Kd, equilibrium dissociation constant; Bmax, receptor density; nH, Hill number.
**P6 0.01 compared with NMDG control; n:s:not statistically signi¢cant.
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Table 2
E¡ects of NaCl (40 mM) and Gpp(NH)p (10 WM) either alone or in combination on competition by di¡erent agonists with
[3H]RX821002 binding to recombinant human K2-adrenoceptors
Drug NaCl Gpp(NH)p Ki (nM) nH KiH (nM) % (high) KiL (nM)
K2A (S115-C10)
(3)-Adrenaline 3 3 44.7 þ 4.8 0.43 þ 0.03 4.68 þ 1.91 61 þ 2 2396 þ 3373
3 + 234 þ 31 0.74 þ 0.04
+ 3 288 þ 66 0.63 þ 0.18 42.4 þ 10.3* 62 þ 3 3211 þ 2973
+ + 976 þ 146 0.72 þ 0.04
(3)-Noradrenaline 3 3 55.9 þ 17.2 0.28 þ 0.01 3.77 þ 1.56 53 þ 2 2298 þ 10253
3 + 546 þ 56 0.80 þ 0.08
+ 3 778 þ 113 0.60 þ 0.04 121 þ 17* 57 þ 3 7492 þ 8763
+ + 2736 þ 254 0.62 þ 0.01
K-Me-Noradrenaline 3 3 284 þ 32 0.65 þ 0.07 32.7 þ 1.8 48 þ 3 1091 þ 643
3 + 786 þ 16 0.68 þ 0.06
+ 3 736 þ 123 0.57 þ 0.02 149 þ 43* 48 þ 2 3640 þ 3943
+ + 2664 þ 205 0.67 þ 0.04
Clonidine 3 3 18.2 þ 1.9 0.57 þ 0.13 0.68 þ 0.26 42 þ 5 45.0 þ 9.03
3 + 53.1 þ 5.1 0.70 þ 0.08
+ 3 8.36 þ 2.03 0.66 þ 0.06 0.36 þ 0.14 33 þ 5 12.7 þ 3.1
+ + 23.3 þ 16.1 1.01 þ 0.18
Dexmedetomidine 3 3 2.37 þ 0.33 0.62 þ 0.06 0.25 þ 0.10 48 þ 8 6.70 þ 1.113
3 + 5.05 þ 0.31 0.80 þ 0.06
+ 3 1.09 þ 0.22 0.67 þ 0.88 0.32 þ 0.09 61 þ 8 5.61 þ 0.673
+ + 4.95 þ 2.81 1.07 þ 0.08
L-Medetomidine 3 3 47.4 þ 5.6 0.76 þ 0.04 0.72 þ 0.26 20 þ 5 83.1 þ 12.3
3 + 54.7 þ 4.1 0.92 þ 0.04
+ 3 53.7 þ 3.2 0.99 þ 0.04 6.43 þ 1.28* 7 þ 4 60.1 þ 1.3
+ + 48.4 þ 5.6 1.00 þ 0.12
UK 14,304 3 3 15.7 þ 0.9 0.63 þ 0.03 2.08 þ 1.14 47 þ 7 68.7 þ 18.43
3 + 31.1 þ 3.3 0.83 þ 0.06
+ 3 25.1 þ 8.3 0.64 þ 0.02 8.76 þ 1.17* 66 þ 3 416 þ 823
+ + 168 þ 22 0.95 þ 0.20
K2B (S115-C2)
(3)-Noradrenaline 3 3 1068 þ 120 0.66 þ 0.06 0.75 þ 0.07 15 þ 1 1249 þ 1733
3 + 2324 þ 450 0.74 þ 0.16
+ 3 2364 þ 501 0.44 þ 0.07 7.34 þ 1.20* 22 þ 4 2958 þ 1403
+ + 4340 þ 651 0.80 þ 0.05
Dexmedetomidine 3 3 5.75 þ 1.64 0.72 þ 0.15 0.19 þ 0.04 21 þ 7 10.1 þ 3.73
3 + 7.30 þ 1.69 0.90 þ 0.07
+ 3 25.4 þ 5.1 0.70 þ 0.07 1.94 þ 0.25* 30 þ 6 65.4 þ 10.83
+ + 36.5 þ 3.3 0.87 þ 0.37
UK 14,304 3 3 858 þ 87 0.62 þ 0.04 4.58 þ 2.38 16 þ 2 1031 þ 1983
3 + 1415 þ 76 0.79 þ 0.10
+ 3 1173 þ 111 0.44 þ 0.05 14.0 þ 4.0* 32 þ 2 2022 þ 1243
+ + 1253 þ 29 0.83 þ 0.01
Clonidine 3 3 72.8 þ 12.9 0.68 þ 0.16 0.32 þ 0.09 28 þ 6 215 þ 28
3 + 188 þ 26 0.83 þ 0.05
+ 3 75.2 þ 17.6 0.80 þ 0.06 3.20 þ 1.06* 25 þ 4 127 þ 3
+ + 159 þ 14 1.00 þ 0.01
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3.2. Competition with [3H]RX821002 binding
The e¡ects of Na on agonist interactions with
recombinant human K2-adrenoceptor subtypes were
¢rst evaluated by performing competition binding
assays with the radioligand [3H]RX821002 at concen-
trations close to its Kd at each receptor subtype. The
competition binding curves of the four to seven
tested K2-adrenoceptor agonists at the three receptor
subtypes were usually best modelled by two-site
¢ts, and showed shallow slopes in one-site models
(Hill number 6 1) (Table 2). In the presence of
Gpp(NH)p agonist competition results were analysed
using both one-site and two-site models. Two-site
models did not provide statistically signi¢cantly bet-
ter ¢ts than one-site models; therefore, only one-site
a⁄nity constants (Ki) are given in Table 2 for the
Gpp(NH)p experiments. As shown in Table 2 and
Fig. 1, the ability of Na to decrease the binding
a⁄nity of (3)-noradrenaline was quite marked at
all three receptor subtypes. High and low a⁄nity
agonist binding states were equally a¡ected. The ef-
fects were largest at the K2A-subtype. The propor-
tions of high a⁄nity binding sites were not in£uenced
by Na ; instead, the biphasic competition curves
were shifted to the right in a parallel fashion, result-
ing in larger KiH and KiL values. At K2A-adrenocep-
tors, NaCl also potently decreased the a⁄nity of
other catecholamine agonists. In contrast, the a⁄n-
ities of clonidine and dexmedetomidine were slightly
increased. The a⁄nity of L-medetomidine was not
in£uenced by NaCl, and the a⁄nity of UK 14,304
was somewhat decreased. At K2B-adrenoceptors, the
a⁄nity of (3)-noradrenaline was reduced by Na to
a clearly lower extent than at K2A-adrenoceptors, and
the a⁄nities of dexmedetomidine and UK 14,304
were markedly reduced. Clonidine binding was only
marginally a¡ected, as shown in Table 2. At
K2C-adrenoceptors, the a⁄nity of dexmedetomidine
was clearly reduced by Na, whereas the a⁄nities
of (3)-noradrenaline and UK 14,304 were only mod-
estly decreased. Clonidine binding at K2C-adrenocep-
tors was not in£uenced by NaCl. The potency order
of monovalent cations to decrease the a⁄nity of
(3)-noradrenaline binding to K2A-adrenoceptors
was NaEKsLi (data not shown).
The tendency to biphasic competition by the ago-
nists for [3H]RX821002 binding (in NMDG or
NMDG+NaCl) was abolished in the presence of 10
WM Gpp(NH)p. The high-a⁄nity components of the
competition binding curves were shifted signi¢cantly
to the right, and the slopes of the curves were clearly
steeper compared to experiments with agonists in the
absence of Gpp(NH)p (Fig. 1). The e¡ects of Na
Table 2 (continued)
Drug NaCl Gpp(NH)p Ki (nM) nH KiH (nM) % (high) KiL (nM)
K2C (S115-C4)
(3)-Noradrenaline 3 3 172 þ 18 0.53 þ 0.03 2.06 þ 1.57 27 þ 4 430 þ 583
3 + 392 þ 69 0.78 þ 0.08
+ 3 462 þ 11 0.58 þ 0.02 2.73 þ 0.74 18 þ 3 631 þ 343
+ + 2201 þ 246 0.77 þ 0.07
Dexmedetomidine 3 3 2.30 þ 1.29 0.73 þ 0.08 0.54 þ 0.19 57 þ 7 18.9 þ 10.23
3 + 4.76 þ 0.55 0.81 þ 0.06
+ 3 21.6 þ 2.11 0.91 þ 0.05 14.5 þ 1.4* 70 þ 3 196 þ 723
+ + 45.8 þ 3.6 1.09 þ 0.08
UK 14,304 3 3 75.9 þ 20 0.61 þ 0.03 27.1 þ 7.2 66 þ 4 922 þ 1213
3 + 276 þ 36 0.85 þ 0.07
+ 3 195 þ 29 0.71 þ 0.05 63.8 þ 20* 57 þ 8 999 þ 403
+ + 409 þ 35 0.85 þ 0.03
Clonidine 3 3 277 þ 15 0.79 þ 0.05 15.5 þ 4.3 31 þ 6 554 þ 133
3 + 341 þ 30 0.89 þ 0.10
+ 3 268 þ 17 0.93 þ 0.07 64.8 þ 6* 50 þ 5 754 þ 473
+ + 391 þ 44 0.91 þ 0.08
Results are means þ S.E. of three separate experiments (or six in some cases), each performed in triplicate.
3Two-site model statistically signi¢cantly better than one-site model (P6 0.05). *Statistically signi¢cantly di¡erent in the presence of
NaCl (P6 0.05).
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ions and Gpp(NH)p on (3)-noradrenaline binding
to K2-adrenoceptors appeared to be additive: the
curves were shifted to the right in a parallel fashion
by Na, whereas Gpp(NH)p abolished the high-af-
¢nity component (Fig. 1). When the dependence of
the binding of a ¢xed concentration of (3)-norad-
renaline (2.7 WM, su⁄cient to reduce speci¢c
[3H]RX821002 binding by 75% in the absence of
Na and by 50% in the presence of 40 mM Na)
on the concentration of Gpp(NH)p was investigated
at K2A-adrenoceptors, similar log-linear relationships
were found both in the absence and presence of Na
(Fig. 2). The e¡ects of Na and the guanine nucleo-
tide thus appeared to be additive.
3.3. Kinetic studies
In order to ensure that the observed di¡erences in
the Na sensitivity of (3)-noradrenaline binding to
Fig. 1. Competition with [3H]RX821002 binding to recombinant
K2-adrenoceptors (A, K2A ; B, K2B ; C, K2C) by (3)-noradrena-
line in the presence (triangles) and absence (circles) of 40 mM
NaCl, without (solid symbols) or with 10 WM Gpp(NH)p (open
symbols). The results represent means þ S.E. of three separate
experiments, each performed in triplicate.
6
Fig. 2. E¡ects of di¡erent concentrations of Gpp(NH)p on the
potency of (3)-noradrenaline (2.7 WM) to compete with
[3H]RX821002 binding to K2A-adrenoceptors in the absence
and presence of Na ions (40 mM NaCl). Data points are
means þ S.E. of four similar experiments, each performed in
triplicate.
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K2-adrenoceptor subtypes were not simply related to
the assay conditions, and to elucidate the mechanism
of the Na e¡ect, some kinetic experiments were also
performed. Addition of (3)-noradrenaline at a con-
centration close to its apparent Ki value resulted in
signi¢cantly greater displacement of [3H]RX821002
in the absence than in the presence of 40 mM
NaCl at all three K2-adrenoceptor subtypes. These
results were ¢tted to single-exponential models. The
resulting apparent [3H]RX821002 dissociation rates,
which partly depend on (3)-noradrenaline associa-
tion kinetics, were not signi¢cantly in£uenced by
Na (0.11^0.14 min31 for K2A, 0.23^0.33 min31 for
K2B, and 0.26^0.29 min31 for K2C). The loss of the
apparent potency of (3)-noradrenaline to compete
with [3H]RX821002 was also not directly related to
the increased receptor a⁄nities for [3H]RX821002
induced by Na. Actually, the reduction in the a⁄n-
ity of (3)-noradrenaline was largest when the in-
crease in the a⁄nity of [3H]RX821002 was smallest,
i.e., at K2A-adrenoceptors (Tables 1 and 2, Fig. 3).
4. Discussion
The interaction of agonists with GPCR is one of
the central aspects of signal transduction across plas-
ma membranes. Radiolabelled ligands o¡er a useful
means to probe this interaction and a wealth of in-
formation has been obtained by this approach. It has
become clear that agonist binding is a complex phe-
nomenon susceptible to allosteric modulation by fac-
tors such as Mg2 and Na ions. In addition, it is
sensitive to experimental manipulations which a¡ect
the interaction of receptors with G-proteins. Based
on a vast body of evidence it is now generally ac-
cepted that GPCRs exist in at least two di¡erent
forms, distinguishable by their a⁄nity for agonists.
Fig. 3. Apparent dissociation of [3H]RX821002 binding after
addition of (3)-noradrenaline in the absence or presence of 40
mM NaCl. (3)-Noradrenaline was added at a concentration
close to its Ki-value in the presence of 40 mM NaCl. The con-
centration of (3)-noradrenaline was 800 nM for K2A (A); 2600
nM for K2B (B); and 500 nM for K2C (C). The results are rep-
resentative of three similar experiments performed in triplicate.
Standard errors were in the range of 0.6^19% and are not
shown for clarity.
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The agonist high-a⁄nity binding sites are believed to
represent ternary complexes consisting of agonist,
activated receptor and guanine nucleotide-free G-
protein while the low-a⁄nity agonist binding sites
are equated with resting receptor forms.
In the current paper we have sought to further
characterise the role of Na ions in the interaction
of agonists with three recombinant human K2-adre-
noceptor subtypes in S115 cells. Considerable di¡er-
ences in the percentage of receptor able to assume
agonist high-a⁄nity forms were noted. Whereas over
50% of the K2A-adrenoceptors in S115-C10 cells dis-
played high a⁄nity for the physiological ligand, the
full agonist (3)-noradrenaline, the proportions were
only about 15^27% for the K2B- and K2C-subtypes.
The presence of a low-a⁄nity component in agonist
competition binding curves under equilibrium condi-
tions argues that not all receptors can simultaneously
couple to G-proteins. Since the number of G-pro-
teins usually exceeds the number of receptors, the
reason for this fairly generally observable lack of
‘coupling capacity’ is not clear. It may have its origin
in a microdomain compartmentation of signal trans-
duction components or in a competition for the pool
of available G-proteins by other receptors. The con-
ceptually simplest way to deal with the lack of cou-
pling capacity is to consider the receptor population
as consisting of two di¡erent subpopulations, an un-
couplable and a couplable one [8].
In the case of the K2B-adrenoceptor in S115-C2
cells, the low percentage of couplable receptor may
be a consequence of the signi¢cantly higher receptor
expression level in S115-C2 (2.8 pmol/mg protein)
compared to S115-C10 cells (0.4 pmol/mg protein).
For the K2C-subtype, a relatively high receptor num-
ber in the S115-C4 cells (1.2 pmol/mg protein) may
not be the only reason for the low degree of coupling
compared to S115-C10 cells. In S115 cells, as also
previously observed in transfected COS-7 and
HEK293 cells [27], K2C-adrenoceptors have immuno-
cytochemically been localised not only to the cell
membrane but also to intracellular structures (T.
Olli-La«hdesma«ki, J. Kallio, M. Scheinin, unpublished
data). Such intracellularly localised receptors may
have less access to G-proteins than those in the plas-
ma membrane, and may consequently be even more
restricted in their ability to form ternary complexes.
Because of the relatively low coupling capacity of
the K2B- and the K2C-adrenoceptors and the conse-
quently larger variability in the experimental results,
the discussion will mainly focus on the K2A-subtype.
Interestingly, the di¡erence among the three
K2-adrenoceptor subtypes in terms of percentages
of coupled receptor was paralleled by di¡erent sensi-
tivities to modulation by Na ions. This pattern is in
agreement with Na ions preferentially a¡ecting the
agonist high-a⁄nity forms of K2-adrenoceptors.
However, Na ions did not only shift the high-a⁄n-
ity portion but also the low-a⁄nity portion of the
agonist competition curves to the right (Fig. 1A^
C). If it is accepted that the low-a⁄nity segment of
the competition curves represents uncouplable recep-
tor, then this obviously means that Na ions modu-
late the receptor also in the absence of any coupling
to G-proteins.
In the competition of [3H]RX821002 binding by
(3)-noradrenaline (Fig. 1A^C), both Gpp(NH)p
and Na ions caused a reduction in agonist a⁄nity.
The e¡ects appeared to be at least additive, since the
presence of both agents promoted a larger decrease
in a⁄nity than either of the two alone. Additivity of
e¡ects was also observed when increasing concentra-
tions of Gpp(NH)p were tested in combination with
40 mM NaCl (Fig. 2). That the ‘uncoupling’ e¡ects
of Na and Gpp(NH)p are mediated via di¡erent
mechanisms can also be inferred from the data in
Table 2, according to which the same percentage of
receptor is accumulated in the form of high-a⁄nity
agonist sites, independent of whether 40 mM NaCl is
present or not. The di¡erence between no Na and
40 mM Na is that higher agonist concentrations are
required in the presence of Na ions. In other words,
the e¡ect of the Na ions can be overcome by in-
creasing the agonist concentration. For Gpp(NH)p
that was not the case. The unsurmountable suppres-
sion of agonist high-a⁄nity binding by guanine nu-
cleotides is considered to be due to an acceleration in
the turnover of ternary complexes, resulting in lower
steady-state levels of such complexes. At high enough
guanine nucleotide concentrations, the lifetime of ter-
nary complexes is so short and their concentration is
so low that essentially all receptors appear to exist in
the agonist low-a⁄nity form. Since the ‘uncoupling’
e¡ect of Na ions is qualitatively di¡erent from that
of Gpp(NH)p, it follows that Na does not act via
such an acceleration of ternary complex turnover.
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The fact that at large enough agonist concentrations
the high-a⁄nity binding component is restored in the
presence of Na furthermore shows that Na does
not prevent the formation of ternary complexes;
rather, it makes their formation more di⁄cult. For
a number of GPCR, such as, e.g., the porcine K2A-
adrenoceptor [9], the modulatory e¡ect of Na has
been linked to an aspartate residue in transmem-
brane domain 2, i.e., the e¡ect is localised in the
receptor protein itself. Taking all these points togeth-
er makes it tempting to speculate that Na may act
by impeding the spontaneous conversion of receptor
from the agonist low-a⁄nity (resting) to the agonist
high-a⁄nity (activated) state. A very similar hypoth-
esis has been put forward for the formyl peptide
receptor in HL60 cells [28] for which the authors
suggested that Na might act by preventing the acti-
vation of G-proteins by unoccupied receptors.
The hypothesis would smoothly integrate the well-
documented e¡ects of Na on spontaneous and re-
ceptor-mediated GTPase or GTPQS-binding activity.
In both types of assays Na ions are known to re-
duce basal activity and to lower agonist potency. If
the assumption is made that receptor-mediated ef-
fects are directly proportional to the fraction of re-
ceptor in the activated state, then the simplest form
of the dynamic receptor concept, the two-state mod-
el, can be used to predict functional responses of
GPCRs [6]. One of the predictions of the two-state
model is that basal activity should be proportional to
the term 1/(1+L) with L being the equilibrium con-
stant for the spontaneous equilibrium between acti-
vated and resting receptor state, L = [R]/[R*]. The
observation that Na reduces basal receptor activity
argues that it does so by increasing L, i.e., by favour-
ing the resting (agonist low-a⁄nity) state R over the
activated (agonist high-a⁄nity) state R*. A second
prediction of the two-state model describes the EC50
of the receptor-mediated function by Eq. 1
EC50  KA
1 L
1 LKA=KA
1
where KA represents the dissociation constant for the
resting state and KA the dissociation constant for the
activated state. Since KA is smaller than KA, the term
1+L grows faster than the term 1+L(KA/KA) when L
increases. Consequently, an increase in L is accom-
panied by an increase in the EC50, i.e., by a loss of
potency. Both the reduction of basal activity and the
loss of agonist potency caused by Na in GTPase
and GTPQS-binding assays can therefore be inter-
preted as manifestations of the same underlying
mechanism, which is a dampening e¡ect of the cation
on spontaneous receptor activation. Indeed, if two
assumptions are accepted, ¢rstly, that the Na e¡ect
is localised in the receptor rather than the G-pro-
tein(s), and secondly, that the two-state model is at
least qualitatively applicable, then this interpretation
follows automatically from the e¡ect of Na on
basal activity. The potency-lowering e¡ect of Na
represents complementing evidence which is circum-
stantial in nature, because the equation for the EC50
contains KA and KA in addition to the equilibrium
constant L. While the e¡ects of Na on the G-pro-
tein responses can be fully accommodated by an in-
crease in L, a concomitant change of KA or KA can-
not be excluded. In fact, when the agonist binding
results in Table 2 are taken into consideration, it
becomes necessary to postulate an e¡ect of Na on
one or both of these dissociation constants. The rea-
son is that if Na would solely increase the ligand-
independent parameter L, the agonist a⁄nity lower-
ing e¡ect of Na would be expected to be observed
for all agonists. However, as the results in Table 2
(K2A-subtype) shows, this was not uniformly the case.
While Na increased the single-site ¢t Kis and the
KiHs for (3)-adrenaline, (3)-noradrenaline, K-meth-
ylnoradrenaline and UK 14,304, those for dexmede-
tomidine and clonidine were unchanged or slightly
decreased. The binding results therefore argue that
the Na e¡ect contains a ligand-dependent compo-
nent, for which KA or KA, either one or both, are the
obvious candidates. When the equilibrium between
resting and activated receptor state is considered in
the form of a reaction coordinate, in which the two
states are represented by their energy levels, an argu-
ment can be deduced, according to which Na ac-
tually should be expected to a¡ect either one or both
of the dissociation constants KA and KA. The posi-
tion of the equilibrium between the two receptor
states is determined by the di¡erence of their energy
levels. As evidenced by their dampening e¡ects on
basal GTPase or GTPQS-binding activity, Na ions
in£uence this equilibrium in the absence of any lig-
and. Obviously, this must mean that Na a¡ects the
di¡erence between the energy levels by shifting either
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one or both of them. The energy levels in the reac-
tion coordinate, however, are expressions of certain
receptor structures. Thus, when the energy level of
one of the states changes, the receptor structure
embodied in it must change, which may result in a
change in ligand a⁄nity for that state.
This line of reasoning touches on the important
point that the activated and resting receptor states
should not be thought of as two ¢xed three-dimen-
sional receptor structures. Rather, the two states
should be considered as the averaged representation
of all of their corresponding conformations with the
population densities of these conformations playing
the role of weighing factors. It should be noted that
the two-state model is a simpli¢ed outline of the
potentially enormously complex dynamic receptor
concept. In principle, any combination of amino
acid residue interactions in a receptor, with a ¢nite
lifetime, has to be considered as a separate receptor
conformation. A complete theoretical description of
how a ligand interacts with a receptor would there-
fore require information about the spontaneous dis-
tribution of the whole receptor population among all
possible conformations plus the knowledge of the
a⁄nities of the ligand for all of these conformations.
The fact that in most cases adequate descriptions of
experimental binding data can be obtained by assum-
ing the existence of only one or two receptor states
or binding sites, respectively, is probably mainly a
re£ection of a lack of analytical resolution. Conceiv-
ably, many receptor conformations are not discrimi-
nated by a given ligand because they involve di¡er-
ences in the interactions of amino acid residues
which do not play a role in the binding of that lig-
and. Other sets of conformations may give rise to
a⁄nity di¡erences, but as long as they are small
with respect to the resolution of available experimen-
tal techniques, they will go undetected.
In summary, the e¡ects of Na ions on agonist
binding to human K2-adrenoceptors presented in
this paper and the well-documented e¡ects of the
cation on G-protein functions in GTPase- and
GTPQS-binding assays can be accommodated by
the hypothesis that Na modulates the energy land-
scape of receptor conformations, thereby favouring
or disfavouring certain receptor conformations. Like
many other GPCR, K2-adrenoceptors are known to
couple to several signal pathways. It may well be
possible that di¡erent receptor conformations are in-
volved in the activation of these separate pathways.
In this context it is highly interesting to note that in
the porcine K2A-adrenoceptor the replacement by tar-
geted mutagenesis of the same amino acid residue
which has been linked to the modulatory e¡ect of
Na (Asp79), does lead to the selective loss of recep-
tor coupling to one of the three pathways activated
by the wild-type receptor, i.e., K channel activation
[29]. Reasoning by analogy, we would therefore like
to propose that the physiological role of receptor
modulation by Na ions might consist in signal traf-
¢cking.
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